Tenax Therapeutics (TENX) Competitors $5.96 +0.08 (+1.36%) Closing price 03:57 PM EasternExtended Trading$5.98 +0.01 (+0.25%) As of 05:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TENX vs. CRBP, OKYO, CHRS, WHWK, VIRI, MGNX, OCX, ZNTL, FBRX, and BYSIShould you be buying Tenax Therapeutics stock or one of its competitors? The main competitors of Tenax Therapeutics include Corbus Pharmaceuticals (CRBP), OKYO Pharma (OKYO), Coherus Oncology (CHRS), Whitehawk Therapeutics (WHWK), Virios Therapeutics (VIRI), MacroGenics (MGNX), OncoCyte (OCX), Zentalis Pharmaceuticals (ZNTL), Forte Biosciences (FBRX), and BeyondSpring (BYSI). These companies are all part of the "pharmaceutical products" industry. Tenax Therapeutics vs. Its Competitors Corbus Pharmaceuticals OKYO Pharma Coherus Oncology Whitehawk Therapeutics Virios Therapeutics MacroGenics OncoCyte Zentalis Pharmaceuticals Forte Biosciences BeyondSpring Tenax Therapeutics (NASDAQ:TENX) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings and risk. Which has stronger valuation & earnings, TENX or CRBP? Tenax Therapeutics is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTenax TherapeuticsN/AN/A-$17.60M-$2.48-2.40Corbus PharmaceuticalsN/AN/A-$40.21M-$4.22-2.01 Which has more volatility and risk, TENX or CRBP? Tenax Therapeutics has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500. Comparatively, Corbus Pharmaceuticals has a beta of 3.05, meaning that its share price is 205% more volatile than the S&P 500. Does the media prefer TENX or CRBP? In the previous week, Corbus Pharmaceuticals had 2 more articles in the media than Tenax Therapeutics. MarketBeat recorded 2 mentions for Corbus Pharmaceuticals and 0 mentions for Tenax Therapeutics. Tenax Therapeutics' average media sentiment score of 1.89 beat Corbus Pharmaceuticals' score of 0.85 indicating that Tenax Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Tenax Therapeutics Very Positive Corbus Pharmaceuticals Positive Is TENX or CRBP more profitable? Tenax Therapeutics' return on equity of -31.51% beat Corbus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Tenax TherapeuticsN/A -31.51% -30.35% Corbus Pharmaceuticals N/A -36.87%-32.87% Do analysts recommend TENX or CRBP? Tenax Therapeutics currently has a consensus price target of $17.50, indicating a potential upside of 193.62%. Corbus Pharmaceuticals has a consensus price target of $50.88, indicating a potential upside of 498.53%. Given Corbus Pharmaceuticals' higher possible upside, analysts clearly believe Corbus Pharmaceuticals is more favorable than Tenax Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tenax Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Corbus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10 Do institutionals and insiders believe in TENX or CRBP? 1.7% of Tenax Therapeutics shares are held by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are held by institutional investors. 3.1% of Tenax Therapeutics shares are held by insiders. Comparatively, 3.6% of Corbus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryCorbus Pharmaceuticals beats Tenax Therapeutics on 7 of the 13 factors compared between the two stocks. Get Tenax Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TENX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TENX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TENX vs. The Competition Export to ExcelMetricTenax TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$24.39M$2.96B$5.54B$9.41BDividend YieldN/A2.46%3.75%4.03%P/E Ratio-2.408.2821.0120.09Price / SalesN/A303.17433.8199.01Price / CashN/A42.5936.1658.27Price / Book0.227.678.125.65Net Income-$17.60M-$55.28M$3.25B$257.91M7 Day Performance2.16%2.50%0.97%2.09%1 Month Performance5.11%11.70%7.36%11.13%1 Year Performance79.52%4.89%31.31%18.40% Tenax Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TENXTenax Therapeutics1.5517 of 5 stars$5.96+1.4%$17.50+193.6%+70.9%$24.39MN/A-2.409CRBPCorbus Pharmaceuticals4.7823 of 5 stars$7.30-5.3%$50.88+596.9%-85.6%$94.35MN/A-1.7340OKYOOKYO Pharma3.1275 of 5 stars$2.82+1.4%$7.00+148.2%+81.3%$94.07MN/A0.007News CoverageGap UpCHRSCoherus Oncology3.7829 of 5 stars$0.75-7.9%$4.68+527.6%-48.5%$93.91M$266.96M-0.66330Gap UpWHWKWhitehawk TherapeuticsN/A$1.98-0.5%N/AN/A$93.75M$25.98M0.0040VIRIVirios Therapeutics0.1115 of 5 stars$4.80-0.6%$5.00+4.2%+1,446.4%$92.44MN/A-17.785News CoverageGap UpMGNXMacroGenics4.3238 of 5 stars$1.36-6.8%$5.71+320.2%-69.9%$92.11M$149.96M-1.53430OCXOncoCyte1.2678 of 5 stars$3.18+16.3%$6.06+90.9%-3.8%$90.80M$3.84M-0.90120ZNTLZentalis Pharmaceuticals2.3466 of 5 stars$1.19-5.6%$8.37+603.1%-66.4%$90.66M$67.43M-0.38160FBRXForte Biosciences3.3927 of 5 stars$12.65-7.4%$61.00+382.2%+42,831.0%$89.93MN/A-0.785Gap DownBYSIBeyondSpringN/A$2.27+1.8%N/A-4.2%$89.90M$1.75M0.0080Gap Up Related Companies and Tools Related Companies Corbus Pharmaceuticals Alternatives OKYO Pharma Alternatives Coherus Oncology Alternatives Whitehawk Therapeutics Alternatives Virios Therapeutics Alternatives MacroGenics Alternatives OncoCyte Alternatives Zentalis Pharmaceuticals Alternatives Forte Biosciences Alternatives BeyondSpring Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TENX) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenax Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenax Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
